Welcome to our dedicated page for Pacira BioSciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira BioSciences stock.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a pioneering company dedicated to advancing non-opioid pain management and regenerative health solutions. Headquartered in Tampa, Florida, Pacira is committed to providing innovative treatments that minimize the reliance on opioids for pain relief, thereby redefining the role of opioids as a rescue therapy only.
Pacira has three primary commercialized products: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and ioveraº®. EXPAREL, launched in 2012, is a long-acting local analgesic used for postsurgical pain management, offering significant reductions in opioid consumption and cumulative pain scores. ZILRETTA, approved in 2017, is an extended-release intra-articular injection aimed at managing osteoarthritis knee pain, providing extended pain relief without repeated administration. ioveraº is a novel handheld device that delivers precise, controlled doses of cold temperature to targeted nerves, offering immediate, drug-free pain relief.
The company’s advanced DepoFoam® delivery platform encapsulates drugs in a multivesicular liposome, releasing them over extended periods without altering their molecular structure. This technology underpins the efficacy of Pacira’s flagship product, EXPAREL, which has been pivotal in reducing opioid use and enhancing postoperative recovery.
Pacira continues to innovate with ongoing clinical developments and strategic initiatives. Recently, the company reported preliminary unaudited total revenue of $675.0 million for the fiscal year 2023. In 2024, Pacira plans to launch EXPAREL for two key lower extremity nerve blocks and anticipates the rollout of the NOPAIN Act in 2025, which will expand patient access to opioid-sparing pain management solutions.
Pacira’s commitment to developing non-opioid treatments is further demonstrated by its recent achievements in securing FDA and European Medicines Agency designations for PCRX-201, a gene therapy product candidate for osteoarthritis. The company’s focus on long-term growth and operational excellence remains steadfast under the leadership of CEO Frank D. Lee.
For more information on Pacira BioSciences and its product offerings, visit www.pacira.com.
Tampa, Fla. – March 27, 2023 – Pacira BioSciences (Nasdaq: PCRX) announced that the U.S. Court of Appeals for the Third Circuit upheld the dismissal of the company’s lawsuit against the American Society of Anesthesiologists. The court determined that the contested findings in Anesthesiology articles were scientific opinions, allowing specialists to assess these as ‘tentative scientific conclusions’. CEO Dave Stack emphasized their commitment to non-opioid alternatives and highlighted that EXPAREL, their long-acting pain management solution, has been used in over 12 million patients. The company aims to enhance patient care through partnerships with medical professionals while expanding the use of EXPAREL.
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced the retirement of independent director Yvonne Greenstreet, effective March 31, 2023, after nine years of service. Dr. Greenstreet, CEO of Alnylam Pharmaceuticals, expressed pride in her contributions to Pacira's growth and emphasized the company's commitment to non-opioid pain management. Pacira is now in the process of selecting a new independent Board member. The company focuses on redefining opioids as a rescue therapy and has three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera, aimed at addressing unmet medical needs.
TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences (NASDAQ: PCRX) announced its participation in an analyst-led fireside chat at the Barclays Global Healthcare Conference on March 15, 2023, at 9:00 AM ET in Miami. The event will be accessible via the company’s website with a two-week replay available post-event.
Pacira focuses on non-opioid therapies, offering three commercial products: EXPAREL for postsurgical pain, ZILRETTA for osteoarthritis knee pain, and ioveraº for drug-free pain control. The company aims to reduce opioid reliance in pain management.
Pacira BioSciences (Nasdaq: PCRX) reported record revenues of $667 million in 2022, a 23% increase from 2021. The company achieved a full-year GAAP net income of $16 million and an adjusted EBITDA of $213 million. However, a fourth quarter GAAP net loss of $10.1 million was reported alongside a 15% decrease in adjusted EBITDA compared to Q4 2021. EXPAREL surpassed 12 million patients, and the company opened a new training center in Houston. For 2023, Pacira forecasts EXPAREL sales of $570 million to $580 million and a non-GAAP gross margin of 76% to 78%.
Pacira BioSciences (Nasdaq: PCRX) has announced a multi-year partnership with the Ladies Professional Golf Association (LPGA), making Pacira’s iovera° the Official Non-Opioid Pain Management Partner. This handheld device utilizes cold therapy to manage pain without medication. Additionally, Pacira will sponsor the LPGA’s fitness trailer and promote non-opioid options during tournaments, with initiatives aimed at educating players about pain management and addressing the opioid crisis. Events in September will feature Pacira distributing purple ribbons for Opioid Awareness Month. The partnership enhances brand visibility and aligns with Pacira’s mission to promote non-opioid solutions.
Pacira BioSciences, Inc. (NASDAQ:PCRX) announced that it will report its fourth quarter and full year 2022 financial results on February 28, 2023, before U.S. markets open. Following this, a live conference call will be held at 8:30 a.m. ET, with an opportunity for pre-registered participants to engage in a Q&A session. Interested parties can access the live audio via the Pacira website, and a replay will be available for two weeks post-call. Pacira is focused on non-opioid pain management solutions, including EXPAREL, ZILRETTA, and iovera, aimed at reducing opioid dependency in patient care.
Pacira BioSciences (PCRX) announced preliminary total revenue of $666.8 million for 2022, a 23.1% increase from $541.5 million in 2021. The 2022 revenue includes product sales from EXPAREL, ZILRETTA, and iovera. Notably, EXPAREL had strong sales with average daily sales at 104% and 107% of the prior year for Q4 and December, respectively. The company ended the year with a solid balance sheet and plans to prepay $50 million of debt, anticipating adjusted EPS of at least $2.50 for 2022.
Pacira BioSciences, Inc. (NASDAQ: PCRX) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 9, 2023, at 3:00 PM PT (6:00 PM EST). Interested parties can access a live audio stream of the event on the company’s investor website, with a replay available for two weeks post-event. Pacira aims to provide non-opioid alternatives for pain management, emphasizing its commitment to reducing opioid dependency. The company has three commercial products: EXPAREL, ZILRETTA, and iovera.
Pacira BioSciences reported preliminary net product sales of $57.5 million for November 2022, a slight decrease from the previous year. EXPAREL sales were $46.0 million, nearly flat compared to $46.5 million in November 2021, with unit volumes increasing by 4%. The company has initiated programs to improve access to EXPAREL, including 340B pricing, which targets 5,200 new accounts. ZILRETTA and iovera° generated $10.0 million and $1.5 million in sales, respectively. The ongoing impacts of COVID-19 are still affecting the elective surgery market, leading to no guidance for 2022 revenue.
On November 17, 2022, a national survey revealed that nearly one in four U.S. adults suffer from chronic knee pain, significantly impacting their daily lives. Conducted by Wakefield Research for Pacira, the survey found that 97% of participants reported negative effects on their daily activities, with many unable to climb stairs or exercise. Notably, 91% missed social events due to pain, and 45% used opioids for management. Concerns about total knee replacement surgery were high, with 88% of patients worried about associated pain and recovery. Innovative non-opioid treatments like iovera° offer promising alternatives.
FAQ
What is the current stock price of Pacira BioSciences (PCRX)?
What is the market cap of Pacira BioSciences (PCRX)?
What is Pacira BioSciences, Inc. known for?
What are Pacira BioSciences' main products?
What is EXPAREL used for?
What recent financial milestone did Pacira achieve?
What is ZILRETTA?
How does ioveraº work?
What is the DepoFoam® delivery platform?
What are Pacira’s plans for 2024?
What is PCRX-201?
Where can I learn more about Pacira BioSciences?
